Beast of pulmonary arterial hypertension burden

Stephen C. Mathai; Vallerie V. McLaughlin

doi:10.1001/jamacardio.2016.3829

Beast of pulmonary arterial hypertension burden

Stephen C. Mathai, Vallerie V. McLaughlin

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	1030-1031
Number of pages	2
Journal	JAMA cardiology
Volume	1
Issue number	9
DOIs	https://doi.org/10.1001/jamacardio.2016.3829
State	Published - Dec 2016

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2016.3829

Cite this

@article{fc49999a89f245e7818bd41fdb582f0d,

title = "Beast of pulmonary arterial hypertension burden",

author = "Mathai, {Stephen C.} and McLaughlin, {Vallerie V.}",

note = "Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mathai reports personal fees from Actelion, Bayer, and Gilead and grants from the National Institutes of Health and the Scleroderma Foundation. Dr McLaughlin reports grants and/or personal fees from Actelion Pharmaceuticals, Arena Pharmaceuticals, Bayer, Gilead Sciences, Steadymed Therapeutics, St Jude Medical, and United Therapeutics. Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mathai reports personal fees from Actelion, Bayer, and Gilead and grants from the National Institutes of Health and the Scleroderma Foundation. Dr McLaughlin reports grants and/or personal fees from Actelion Pharmaceuticals, Arena Pharmaceuticals, Bayer, Gilead Sciences, Steadymed Therapeutics, St Jude Medical, and United Therapeutics.",

year = "2016",

month = dec,

doi = "10.1001/jamacardio.2016.3829",

language = "English (US)",

volume = "1",

pages = "1030--1031",

journal = "JAMA cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Beast of pulmonary arterial hypertension burden

AU - Mathai, Stephen C.

AU - McLaughlin, Vallerie V.

N1 - Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mathai reports personal fees from Actelion, Bayer, and Gilead and grants from the National Institutes of Health and the Scleroderma Foundation. Dr McLaughlin reports grants and/or personal fees from Actelion Pharmaceuticals, Arena Pharmaceuticals, Bayer, Gilead Sciences, Steadymed Therapeutics, St Jude Medical, and United Therapeutics. Funding Information: completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mathai reports personal fees from Actelion, Bayer, and Gilead and grants from the National Institutes of Health and the Scleroderma Foundation. Dr McLaughlin reports grants and/or personal fees from Actelion Pharmaceuticals, Arena Pharmaceuticals, Bayer, Gilead Sciences, Steadymed Therapeutics, St Jude Medical, and United Therapeutics.

PY - 2016/12

Y1 - 2016/12

UR - http://www.scopus.com/inward/record.url?scp=85037159238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037159238&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2016.3829

DO - 10.1001/jamacardio.2016.3829

M3 - Comment/debate

AN - SCOPUS:85037159238

SN - 2380-6583

VL - 1

SP - 1030

EP - 1031

JO - JAMA cardiology

JF - JAMA cardiology

IS - 9

ER -

Beast of pulmonary arterial hypertension burden

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this